Newsroom

LOTTE BIOLOGICS (CEO Richard W. Lee) has announced its participation in the 2024 BIO International Convention (BIO USA), to be held from June 3 to 6 in San Diego, USA.

'Bio USA' is the world's largest biotechnology and pharmaceutical exhibition hosted annually by the American Biotechnology Association. LOTTE BIOLOGICS' which has participated for three consecutive years since 2022, will be hosting dedicated booth, where a comprehensive introduction of the company is planned for visitors, and the private meeting room will be used as a space for partnering discussions with global pharmaceutical companies and bio ventures, as well as for private meetings with visitors.

At this event, detailed plant designs will be presented for the ADC manufacturing facility of the Syracuse Bio Campus, currently under expansion with operations planned for next year, and for the Songdo Bio Campus Plant 1, which commenced construction last March and will have a manufacturing capacity of 120,000 liters. It will showcase the facility’s ability to quickly respond to the diverse needs of potential clients through the complementary manufacturing strategies of both campuses, ranging from large-scale antibody drugs to ADC manufacturing.

In particular, the company explains that Syracuse Bio Campus has track records of transferring multiple raw materials to key personnel, and five of them have already been commercialized. In addition, ADC production facilities are also targeted for startup next year, enabling the company to provide antibody-ADC one-stop service in the United States.

With Syracuse Bio Campus in the United States and the Songdo Bio Campus as the base, the company plans to establish CDMO hubs in the United States and Asia and will continue to strengthen sales and networks through the recently opened Boston sales office.

Kyoung E. Kim, Head of Business Development at LOTTE BIOLOGICS, stated, "With the completion of the ADC facility at the Syracuse Bio Campus and the establishment of Plant 1 at the Songdo Bio Campus on the horizon, we aim to strengthen our partnerships at BIO USA. Leveraging the synergy and excellence of our production facilities in Korea and the United States, LOTTE BIOLOGICS is poised to rapidly ascend the ranks of the global top 10 CDMO companies."

Since its founding in June 2022, LOTTE BIOLOGICS has actively participated in global pharmaceutical and biotech events, including CPhI Worldwide and the JP Morgan Healthcare Conference, operating dedicated booths and delivering keynote presentations.